Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer
- PMID: 30842876
- PMCID: PMC6388024
- DOI: 10.1098/rsfs.2018.0077
Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer
Abstract
The initial part of this review details the controversy behind the use of a serological level of prostate-specific antigen (PSA) for the diagnostics of prostate cancer (PCa). Novel biomarkers are in demand for PCa diagnostics, outperforming traditional PSA tests. The review provides a detailed and comprehensive summary that PSA glycoprofiling can effectively solve this problem, thereby considerably reducing the number of unnecessary biopsies. In addition, PSA glycoprofiling can serve as a prognostic PCa biomarker to identify PCa patients with an aggressive form of PCa, avoiding unnecessary further treatments which are significantly life altering (incontinence or impotence).
Keywords: biomarkers; diagnostics; glycans; lectins; prostate cancer; prostate-specific antigen.
Conflict of interest statement
We declare we have no competing interests.
Figures


References
-
- O'Reilly J-A, O'Kennedy RJ. 2017. Prostate cancer detection: complexities and strategies. J. Cancer Treat. Diagn. 2, 18–25.
-
- Rodríguez JZ, O'Kennedy R. 2017. New approaches for the development of diagnostic systems for prostate cancer. Asian Hosp. Healthc. Manag. 36, 18–23.
-
- Ablin RJ, Piana R. 2014. The great prostate hoax: how big medicine hijacked the PSA test and caused a public health disaster. New York, NY: Palgrave McMillian.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous